



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

FILE COPY

November 13, 2002

Mr. Gary L. Yingling
Kirkpatrick & Lockhart, LLP et al
1800 Massachusetts Ave., N.W.
Washington, D.C. 20036-1221

Dear Mr. Yingling:

Your petition requesting the Food and Drug Administration to take the following actions regarding with respect to exceptive drug products, including single ingredient extended release guaifenesin drug products, was received by this office on 11/13/02. It was assigned docket number 02P-0483/CP1 and it was filed on 11/13/02. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Helen K. Harris
Dockets Management Branch

cc:

David L. Durkin
Olsson, Frank & Weeda, P.C.
1400 Sixteenth Street, N.W., Suite 400
Washington, D.C. 20036-2220

David L. Rosen, R.Ph., J.D.
McDermott, Will & Emery
600 13th Street, N.W.
Washington, D.C. 20005-3096

Peter R. Mathers
Kleinfeld, Kaplan & Becker, LLP
1140 Nineteenth Street, N.W.
Washington, D.C. 20036

02P-0483

ACK1